Durvalumab activity in previously treated patients who stopped durvalumab without disease progression

BACKGROUND: Limited data exist on potential clinical benefit with anti-programmed cell death ligand-1 (PD-L1) retreatment in patients who stop initial therapy for reasons other than disease progression or toxicity and develop disease progression while off treatment. PATIENTS AND METHODS: NCT01693562...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheth, Siddharth, Gao, Chen, Mueller, Nancy, Angra, Natasha, Gupta, Ashok, Germa, Caroline, Martinez, Pablo, Soria, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451272/
https://www.ncbi.nlm.nih.gov/pubmed/32847985
http://dx.doi.org/10.1136/jitc-2020-000650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451272/
https://www.ncbi.nlm.nih.gov/pubmed/32847985
http://dx.doi.org/10.1136/jitc-2020-000650

Ejemplares similares